{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-099017","form_type":"8-K","ticker":"TVRD","cik":"0001346830","company_name":"Tvardi Therapeutics, Inc.","filed_at":"2022-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.479107+00:00","generated_at":"2026-06-23T10:49:30.605259+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cara Therapeutics appoints Ryan Maynard as CFO, effective Sept 12, 2022","bullets":["Ryan Maynard appointed CFO effective September 12, 2022; principal financial and accounting officer.","Compensation: $460,000 base salary, 40% target bonus, 225,000 share option grant vesting over 4 years.","Maynard previously CFO of LetsGetChecked and Rigel Pharmaceuticals (10 years as CFO at Rigel).","Appointment aligns with ongoing launch of KORSUVA injection for chronic pruritus."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-099017","json":"https://secwatch.observer/filing/0001104659-22-099017.json","markdown":"https://secwatch.observer/filing/0001104659-22-099017.md","text":"https://secwatch.observer/filing/0001104659-22-099017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1346830/000110465922099017/0001104659-22-099017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1346830/000110465922099017/tm2225550d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T10:49:30.605259+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c27ab4d18d","claim":"Ryan Maynard was appointed as Chief Financial Officer at Tvardi Therapeutics, Inc..","evidence_excerpt":"announced the appointment of Ryan Maynard to serve as Chief Financial Officer of the Company, effective September 12, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1346830/000110465922099017/0001104659-22-099017-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}